Olaratumab Access Program for Patients with Soft Tissue Sarcoma

Sponsor: Eli Lilly and Company

Expanded Access
Approved for Marketing
Sponsor score: 60
Inactive

ClinicalTrials ID:NCT03994627

Provider View

This program allows patients with soft tissue sarcoma who are already receiving the drug olaratumab to continue their treatment. It is designed for those whose cancer cannot be cured with surgery or radiation.

Patient Parameters

Program Overview

The aim of this program is to ensure that patients with soft tissue sarcoma (STS), who are already being treated with the drug olaratumab, can continue to receive it. This is specifically for patients whose cancer has spread or is too advanced to be removed by surgery or treated with radiation.

Eligibility Criteria

Inclusion Criteria

  • Currently receiving olaratumab and wish to continue treatment after discussing with their doctor.
  • Have soft tissue sarcoma that has spread or is too advanced to be removed by surgery or treated with radiation.
  • Have signed a consent form agreeing to participate.
  • Have a certain level of white blood cells (neutrophils) in their blood.
  • Women who can become pregnant and men must agree to use effective birth control during treatment and for 3 months after the last dose. Effective methods include implants, injections, birth control pills, some IUDs, abstinence, or having a partner who has had a vasectomy.

Exclusion Criteria

  • Currently breastfeeding (patients who stop breastfeeding can participate).

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.